Is lean mass the same as muscle mass?

No. DXA lean mass includes skeletal muscle, organs, connective tissue, skin, and body water; it is not a direct measurement of muscle tissue alone. Hydration and glycogen can also affect the estimate. That is why clinicians consider strength and physical function alongside body-composition results instead of translating every kilogram of lean-mass change into a kilogram of lost muscle.

How much lean mass was lost with semaglutide in STEP 1?

Total lean body mass fell 9.7% from baseline in the STEP 1 DXA substudy, while total fat mass fell 19.3% and visceral fat mass fell 27.4%. One absolute-mass analysis represented about 40% of the observed weight reduction as lean mass. These are averages from an exploratory 140-person substudy, not a forecast for an individual patient.

Can protein and resistance training prevent muscle loss on a GLP-1?

They may help protect lean tissue, but neither is a guarantee. Resistance training has preserved lean mass in small calorie-restriction trials, while trials of higher protein alone in older adults have produced mixed results. A clinician or dietitian can individualize nutrition and activity around kidney function, baseline strength, food intake, balance, joint health, and other medical limitations.

Who has the greatest concern about semaglutide muscle loss?

Older adults and people starting with low strength or limited muscle reserve deserve closer attention. Frailty, chronic kidney disease, type 2 diabetes, repeated weight cycling, and very low intake can add risk. New trouble rising from a chair, climbing stairs, carrying ordinary items, or maintaining balance is more clinically meaningful than a consumer scale's muscle estimate alone.

Does tirzepatide preserve more lean mass than semaglutide?

That has not been established by a head-to-head body-composition trial. The SURMOUNT-1 DXA substudy attributed 26% of tirzepatide-associated weight loss to lean mass, while an absolute-mass analysis of STEP 1 put the semaglutide share near 40%. Different participants, durations, analyses, and trial designs mean those percentages cannot reliably rank the two medications for muscle preservation.

Does Semaglutide Cause Muscle Loss?

Does semaglutide cause muscle loss? It can be accompanied by a drop in lean mass as body weight falls, but that is not the same as proving semaglutide directly breaks down skeletal muscle. In STEP 1, DXA scans showed that absolute lean mass decreased while fat mass decreased much more. The proportion of body weight made up of lean mass therefore rose. The practical goal is not simply to defend a scan number; it is to preserve strength, mobility, and enough lean tissue during substantial weight loss.

Does semaglutide cause muscle loss in STEP 1?

The best-known answer comes from an exploratory body-composition analysis within STEP 1. In that substudy, 140 adults had dual-energy X-ray absorptiometry, usually shortened to DXA, during 68 weeks of treatment with semaglutide 2.4 mg or placebo alongside lifestyle intervention.

Among participants assigned semaglutide, body weight fell 15.0% in the DXA substudy. Total fat mass fell 19.3%, regional visceral fat mass fell 27.4%, and total lean body mass fell 9.7%. Because fat declined faster than lean tissue, lean mass increased by 3.0 percentage points as a share of total body weight (Wilding et al., Journal of the Endocrine Society 2021).

That is the honest two-part answer: absolute lean mass went down, while overall body composition shifted toward a higher proportion of lean mass. The substudy was exploratory and much smaller than the full STEP 1 trial, so its percentages are group averages, not a prediction for one person. The broader weight outcomes belong in the detailed semaglutide weight-loss results review.

Lean mass is not the same as skeletal muscle

A DXA scan divides the body into fat mass, bone mineral, and lean soft tissue. That lean category includes skeletal muscle, but also organs, connective tissue, skin, and body water. Hydration and glycogen changes can move the result. A 9.7% decline in DXA lean mass therefore cannot be translated into “9.7% of muscle disappeared.”

Muscle health is also functional. Strength, walking speed, balance, and the ability to rise from a chair may matter more than a single lean-mass estimate. STEP 1 was not designed to diagnose sarcopenia, and its DXA analysis did not establish that semaglutide directly caused muscle tissue loss independent of the energy deficit and weight loss it produced.

The quarter rule puts GLP-1 muscle loss in context

Weight loss from calorie restriction, medication, or bariatric surgery rarely comes entirely from fat. A commonly cited rule says roughly one-quarter of lost weight may be fat-free mass and three-quarters fat. A critical review found that the “quarter rule” is useful context, not a biological constant: age, starting body composition, protein intake, physical activity, rate of loss, and the measurement method can all change the split (Heymsfield et al., Obesity Reviews 2014).

The semaglutide DXA result landed above that rough benchmark, with about 40% of the observed loss represented by lean mass in one absolute-mass analysis. That does not prove a unique muscle-wasting effect. It does make the prevention question worth taking seriously.

For comparison, the 160-person SURMOUNT-1 DXA substudy reported that tirzepatide-associated weight loss was 74% fat mass and 26% lean mass at 72 weeks; absolute lean mass fell 10.9% (Look et al., Diabetes, Obesity and Metabolism 2025). These were separate substudies, not a head-to-head body-composition trial, so the percentages cannot establish which medication preserves more muscle. Tirzepatide versus semaglutide owns the broader comparison.

Why older adults deserve extra attention

Sarcopenia means more than having less lean mass. It involves low muscle strength, low muscle quantity or quality, and, when severe, reduced physical performance. Aging already narrows the reserve. Frailty, low baseline strength, chronic kidney disease, type 2 diabetes, repeated weight cycling, and very low food intake can narrow it further.

The concern is real, but the evidence is incomplete. Reviews of GLP-1 therapy in older and medically complex groups find that dedicated body-composition and functional data remain scarce; they call for closer assessment rather than assuming every lean-mass change is sarcopenia (Scheen, Diabetes & Metabolism 2025). For someone who begins with low muscle reserve, a modest additional loss can matter more than a larger loss in someone strong and active.

What a prescriber discusses to protect muscle

There is no validated semaglutide-specific muscle-preservation protocol. A useful clinical discussion covers four practical levers:

Adequate protein and total nutrition. Appetite suppression can make both calories and protein fall sharply. A clinician or dietitian can individualize intake around age, body size, kidney function, food preferences, and the pace of weight loss. More protein is not a guarantee: in a randomized trial of 61 older adults, 1.7 versus 0.9 grams per kilogram per day did not produce a significant difference in lean-mass loss during calorie restriction (Backx et al., International Journal of Obesity 2016).
Progressive resistance exercise. This gives muscle a reason to stay. In a small 16-week randomized study of adults aged 60 to 75, both groups followed a high-protein energy-restricted diet, but lean mass declined only in the group without resistance training (Amamou et al., Journal of Nutrition, Health & Aging 2017). The exact program should match current ability, joint health, balance, and medical limitations.
A tolerable pace. When nausea, early fullness, or other symptoms make adequate intake difficult, a prescriber may delay escalation or choose a slower titration. No dedicated trial has shown slower titration itself preserves muscle; the purpose is to improve tolerability and avoid an unnecessarily steep nutrition deficit. The prescriber sets the actual dose.
Measurements that include function. Weight trend, dietary intake, strength, and day-to-day function provide more context than a consumer scale’s muscle estimate. A clinician may add DXA, grip strength, or a chair-rise test when baseline frailty or a meaningful decline raises concern.

At Promise, a licensed provider reviews every request; not everyone qualifies for semaglutide, and the provider may prescribe or decline based on medical eligibility.

When a change deserves a clinical review

A falling scale number alone does not identify dangerous muscle loss. New difficulty rising from a chair, carrying ordinary groceries, climbing stairs, keeping balance, or completing usual activity is more informative. So is a sustained inability to eat enough because of nausea or unusually strong appetite suppression.

Those changes deserve review before the next dose decision. The clinician can look for medication intolerance, dehydration, an overly large energy deficit, illness, or another cause of weakness, then decide whether nutrition support, a change in activity, testing, or an adjustment to treatment is appropriate.